Randomized Study of Beta Interferon and Thalidomide in Patients With Adrenoleukodystrophy - Related Studies

Randomized Study of Beta Interferon and Thalidomide in Patients With Adrenoleukodystrophy

This study has been completed.

Study NCT00004450. Last updated on June 23, 2005. Information provided by FDA Office of Orphan Products Development

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Adrenoleukodystrophy

2	Additional conditions recognized in this trial
		Addison Disease

3	More general conditions related to this trial
		Adrenal Gland Diseases
		Adrenal Insufficiency
		Autoimmune Diseases
		Brain Diseases
		Brain Diseases, Metabolic
		Brain Diseases, Metabolic, Inborn
		Central Nervous System Diseases
		Demyelinating Diseases
		Endocrine System Diseases
		Genetic Diseases, Inborn
		Genetic Diseases, X-Linked
		Hereditary Central Nervous System Demyelinating Diseases
		Heredodegenerative Disorders, Nervous System
		Immune System Diseases
		Mental Retardation
		Mental Retardation, X-Linked
		Metabolic Diseases
		Metabolism, Inborn Errors
		Nervous System Diseases
		Neurobehavioral Manifestations
		Neurologic Manifestations
		Peroxisomal Disorders

4	Interventions listed in this trial
		glyceryl trierucate
		glyceryl trioleate
		interferon beta
		thalidomide

5	Additional drug interventions recognized in this trial
		Interferon Alfa-2b
		Interferon-beta
		Interferons

6	More general drug interventions related to this trial
		Angiogenesis Inhibitors
		Angiogenesis Modulating Agents
		Anti-Bacterial Agents
		Anti-Infective Agents
		Antineoplastic Agents
		Antiviral Agents
		Growth Inhibitors
		Growth Substances
		Immunologic Factors
		Immunosuppressive Agents
		Leprostatic Agents
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

7	Sponsors listed in this trial
		FDA Office of Orphan Products Development
		Kennedy-Krieger Research Institute